News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Paige Biopharmaceutical-B (02565.HK) Innovative Candidate CR059 Selected as ADA Latest Breaking Abstract
Paige Biopharmaceutical-B (02565.HK) announced that a research abstract related to its self-developed innovative candidate CR059 has been accepted by the American Diabetes Associat...
Reset
Send
The window will close in 5 seconds
Paige Biopharmaceutical-B (02565.HK) Innovative Candidate CR059 Selected as ADA Latest Breaking Abstract
Close
Recommend
3
Positive
1
Negative
2
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Paige Biopharmaceutical-B (02565.HK)  0.000 (0.000%)    Short selling $1.52M; Ratio 8.547%   announced that a research abstract related to its self-developed innovative candidate CR059 has been accepted by the American Diabetes Association (ADA) for presentation at the ADA 2026 Scientific Sessions and has been selected as a latest breaking abstract. The study will be presented in poster format.

According to the research results, CR059 demonstrated significant weight-loss effects, outstanding glucose-lowering performance and long-term expression characteristics, indicating its development potential as a long-acting therapeutic solution for metabolic diseases. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.